Coloplast ASCLPBF +6.27%72 ROC (Joel Greenblatt) % is -33.64% as of Mar. 2026. GuruFocus rates CLPBF with a GF Score™ of 72/100 and a GF Value™ of $126.25 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 840 Medical Devices & Instruments companies, Coloplast AS ranks better than 83.1% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Coloplast AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -33.64%.
The historical rank and industry rank for Coloplast AS's ROC (Joel Greenblatt) % or its related term are showing as below:
CLPBF'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 36.37 Med: 102.09 Max: 145.33
Current: 36.37
During the past 13 years, Coloplast AS's highest ROC (Joel Greenblatt) % was 145.33%. The lowest was 36.37%. And the median was 102.09%.
CLPBF's ROC (Joel Greenblatt) % is ranked better than 83.1% of 840
companies
in the Medical Devices & Instruments industry
Industry Median: 4.035
vs CLPBF: 36.37
Coloplast AS's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was -8.70% per year.
Coloplast AS (OTCPK:CLPBF) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Coloplast AS ROC (Joel Greenblatt) % Related Terms
Coloplast AS ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Coloplast AS's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CLPBF vs ISRG, BDX, MDLN: ROC (Joel Greenblatt) % Comparison
For the Medical Instruments & Supplies subindustry, Coloplast AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coloplast AS ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coloplast AS's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Coloplast AS's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -33.64% mean?
Coloplast AS (CLPBF) has a ROC (Joel Greenblatt) % of -33.64% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Coloplast AS and its competitors. Over the past decade, Coloplast AS's ROC (Joel Greenblatt) % has ranged from 36.37 to 145.33. According to the industry distribution chart, Coloplast AS ranks #142 out of 840 companies in the Medical Devices & Instruments industry, placing it in the top 16.9%.
Is Coloplast AS's ROC (Joel Greenblatt) % too high?
Coloplast AS's current ROC (Joel Greenblatt) % is -33.64%. Over the past 10 years, this metric has ranged from a low of 36.37 to a high of 145.33. Based on the distribution chart, Coloplast AS ranks #142 out of 840 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Coloplast AS has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's ROC (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coloplast AS ranks #142 out of 840 companies for ROC (Joel Greenblatt) %. This places Coloplast AS in the top 17% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 4.04. Historically, Coloplast AS's own ROC (Joel Greenblatt) % has ranged from 36.37 to 145.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 4.04, based on 840 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Coloplast AS and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 4.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coloplast AS's current ROC (Joel Greenblatt) % is -33.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (CLPBF) is currently considered Significantly Undervalued. The stock's GF Value™ is $126.25, compared to a current price of $60.47 — trading 52.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is -33.64%. Coloplast AS's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Coloplast AS (CLPBF), the current ROC (Joel Greenblatt) % is -33.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coloplast AS (CLPBF) Overvalued in 2026?
Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued.
The current stock price of $60.47 is trading 52.1% below its estimated GF Value™ of $126.25.
GuruFocus considers Coloplast AS to be Significantly Undervalued.
Key valuation signals for CLPBF:
ROC (Joel Greenblatt) %: -33.64%
GF Value™: $126.25 vs. price of $60.47 (52.1% below fair value)
No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score
Get the complete analysis for CLPBF
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLPBF has been successfully added to your 
